A post hoc look at phase 3 ICONIC data found similar efficacy, safety and drug levels in 31 GLP-1 users. The researchers note the small sample limits the conclusions.
Recap by typeshit. Full story at Rheumatology Advisor.
The 1,200-person trial starts next year with MIT and Pitt researchers, funded by a $13 million Arnold Ventures grant, and will also track housing and jobs.
Researchers found the peptide they built as a treatment already circulates in human blood, at lower levels in people with cognitive impairment.
Lilly Medical points to newly published results from a double-blind, placebo-controlled phase 3 study of its triple-hormone shot in people with diabetes.
Topol points to work suggesting the body's own GLP-1 family peptides help reduce inflammation in the gut. Details are thin, so tap through for the study.
12:50
Alex Wallace, who bills himself as a peptide expert, gives his response to what Dr. Mike has said about peptides. Details beyond the title are thin.
Bloomberg says the boom in GLP-1 use has opened a risky trade in weight loss drugs brought into Brazil illegally.
Loading…